{"url_path":"/sec/gtbp/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/109657/0001493152-26-023346-index.html","accession_number":"0001493152-26-023346","cik":"0000109657","ticker":"GTBP","issuer_name":"GT Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/109657/0001493152-26-023346-index.html","primary_entity_key":"0000109657","primary_entity_name":"GT Biopharma, Inc."},"word_count":114,"has_tables":true,"body_markdown":"**Item\n2. Unregistered Sales of Equity Securities and Use of Proceeds**\n\n \n\nDuring the first quarter of 2026, the Company issued\nsecurities in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, in the amounts and for\nthe consideration set forth below:\n\n \n\nOn April 1, 2026, the Company issued 267,749 shares\nof Common Stock to the holders of Series L Preferred Stock of record as of March 19, 2026 as a dividend, which represents 10% of the outstanding\nstated value of the Series L Preferred Stock.\n\n \n\nAny other issuances of unregistered equity securities\nduring the three months ended March 31, 2026 have previously been disclosed in filings with the SEC."}